Chronic Spontaneous Urticaria on Omalizumab Therapy and Latent Tuberculosis Infection: A New Case Report  

作　　者：Waqas S. Abdulwahhab Fatima M. Al Qaydi Waqas S. Abdulwahhab;Fatima M. Al Qaydi(Department of Dermatology and Venereology, Al Qassimi Hospital, Sharjah, UAE;College of Medicine, Sharjah University, Sharjah, UAE;Dubai Health Authority, Dubai, UAE)

机构地区：[1]Department of Dermatology and Venereology, Al Qassimi Hospital, Sharjah, UAE [2]College of Medicine, Sharjah University, Sharjah, UAE [3]Dubai Health Authority, Dubai, UAE

出　　处：《Journal of Cosmetics, Dermatological Sciences and Applications》2023年第1期33-37,共5页化妆品、皮肤病及应用期刊（英文）

摘　　要：Background: Chronic Spontaneous urticarial (CSU) is a common dermatological problem characterized by recurrent pruritic or burning wheals last less than 24 hours and treated by many modalities of therapy including systemic antihistamines and in refractory cases with Omalizumab anti-IgE antibody biological injection. Latent tuberculosis infection (LTBI) is diagnosed based on a positive tuberculin skin test or QuantiFERON-TB test without evidence of active tuberculosis. Aim: To document a new case report of a patient with a history of CSU and latent tuberculosis on Omalizumab therapy during Isoniazid (INH) prophylaxis. Case Report: A-53-year-old woman with a history of CSU and newly identified LTBI who have been treated with INH monotherapy before starting Omalizumab injection followed up over 24 weeks course of therapy for any sign of tuberculosis reinfection. Conclusion: Omalizumab injection was used effectively for the treatment of CSU in a patient with latent tuberculosis infection with minimal risk of tuberculosis reactivation.Background: Chronic Spontaneous urticarial (CSU) is a common dermatological problem characterized by recurrent pruritic or burning wheals last less than 24 hours and treated by many modalities of therapy including systemic antihistamines and in refractory cases with Omalizumab anti-IgE antibody biological injection. Latent tuberculosis infection (LTBI) is diagnosed based on a positive tuberculin skin test or QuantiFERON-TB test without evidence of active tuberculosis. Aim: To document a new case report of a patient with a history of CSU and latent tuberculosis on Omalizumab therapy during Isoniazid (INH) prophylaxis. Case Report: A-53-year-old woman with a history of CSU and newly identified LTBI who have been treated with INH monotherapy before starting Omalizumab injection followed up over 24 weeks course of therapy for any sign of tuberculosis reinfection. Conclusion: Omalizumab injection was used effectively for the treatment of CSU in a patient with latent tuberculosis infection with minimal risk of tuberculosis reactivation.

关 键 词：Chronic Spontaneous Urticaria Latent Tuberculosis OMALIZUMAB QuantiFERON-TB Test 

分 类 号：R97[医药卫生—药品]